Engineers Gate Manager’s Catalyst Pharmaceutical CPRX Stock Holding History

Engineers Gate Manager’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Buy	87,867 +20,806	+31%	+$614K	0.04%	558
2026 Q1	$1.66M	Buy	67,061 +18,922	+39%	+$451K	0.02%	797
2025 Q4	$1.12M	Sell	48,139 -95,525	-66%	-$2.13M	0.01%	972
2025 Q3	$2.83M	Buy	143,664 +87,522	+156%	+$1.8M	0.03%	601
2025 Q2	$1.22M	Buy	+56,142	New	+$1.33M	0.02%	1017
2025 Q1	–	Sell	-42,737	Closed	-$892K	–	2222
2024 Q4	$892K	Sell	42,737 -4,159	-9%	-$89.3K	0.02%	1081
2024 Q3	$932K	Sell	46,896 -39,652	-46%	-$735K	0.02%	1035
2024 Q2	$1.34M	Sell	86,548 -60,407	-41%	-$940K	0.03%	750
2024 Q1	$2.34M	Buy	+146,955	New	+$2.21M	0.06%	421
2023 Q4	–	Sell	-102,731	Closed	-$1.2M	–	2012
2023 Q3	$1.2M	Buy	+102,731	New	+$1.37M	0.04%	600
2023 Q2	–	Sell	-26,011	Closed	-$431K	–	1781
2023 Q1	$431K	Buy	+26,011	New	+$429K	0.02%	1052
2022 Q4	–	Sell	-38,274	Closed	-$491K	–	1724
2022 Q3	$491K	Sell	38,274 -21,965	-36%	-$260K	0.03%	822
2022 Q2	$422K	Buy	60,239 +18,794	+45%	+$138K	0.02%	1205
2022 Q1	$344K	Buy	+41,445	New	+$293K	0.01%	1301
2021 Q4	–	Sell	-15,395	Closed	-$82K	–	2052
2021 Q3	$82K	Sell	15,395 -30,708	-67%	-$168K	﹤0.01%	1553
2021 Q2	$265K	Sell	46,103 -9,963	-18%	-$51.4K	0.02%	1218
2021 Q1	$258K	Buy	56,066 +42,870	+325%	+$170K	0.01%	1418
2020 Q4	$44K	Sell	13,196 -208,162	-94%	-$699K	﹤0.01%	1640
2020 Q3	$657K	Buy	+221,358	New	+$866K	0.03%	842
2015 Q2	–	Sell	-14,882	Closed	-$64K	–	1044
2015 Q1	$64K	Buy	+14,882	New	+$53.6K	0.01%	903

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Engineers Gate Manager's CPRX Position: Q2 2026 in Review

Engineers Gate Manager increased its Catalyst Pharmaceutical (CPRX) stake by 31% in Q2 2026, buying an estimated $614K and bringing the position to 87,867 shares worth $2.76M. The position accounts for 0.04% of the portfolio, ranked #558.

Engineers Gate Manager first reported a position in CPRX in Q1 2015 and has held it in 20 quarters since. The position peaked at $2.83M in Q3 2025. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Engineers Gate Manager held 87,867 shares of Catalyst Pharmaceutical worth $2.76M as of Q2 2026.
Engineers Gate Manager bought 20,806 Catalyst Pharmaceutical shares in Q2 2026, an estimated $614K.
Catalyst Pharmaceutical made up 0.04% of Engineers Gate Manager's portfolio in Q2 2026, its #558 holding.
Engineers Gate Manager first reported a position in Catalyst Pharmaceutical in Q1 2015 and has held it in 20 quarters since.
Engineers Gate Manager's Catalyst Pharmaceutical position peaked at $2.83M in Q3 2025.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.